Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...
In this video, Halle C. F. Moore, MD, discusses the EMBER-3 study update evaluating imlunestrant for women with hormone receptor-positive, HER2-negative breast cancer, presented at San Antonio Breast ...
When it comes to depicting raw, emotional honesty about the societal expectations placed on trans women, Geena Rocero is not ...
SurvivorNet on MSN
Enabling hope: Lilly’s head of oncology has a hugely ambitious plan to create the next wave of cancer drugs & incredible resources to make it happen
For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...
The hit Japanese Netflix series is returning with high stakes, deadlier battles and new mysteries, as Kodoku continues his ...
“For many years, the standard of care for ASHL was based on the RATHL trial, where newly diagnosed patients were given two cycles of ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] and ...
This weekend’s streaming picks across new movies and shows range from thrillers to comedies, including "Fallout," "Emily in Paris" and "Running Man" ...
In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval of pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia or small ...
From Dhak Dhak girl to serial killer using her devious mind to help the cops hunt down a copycat criminal, Madhuri Dixit ...
The article 🌱 Patch AM: What Grand Rapids’ mayor says is coming for your neighborhood in 2026 appeared first on Grand Rapids ...
The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback